Putting Pain on Ice: FDA Opens a New Chapter in Injectable Nerve Treatment

On August 21, 2026, the FDA granted De Novo authorization to Brixton Biosciences’ ReneuRx (Neural Ice), establishing a Class II category for injectable devices that treat musculoskeletal pain through thermal energy exchange.